Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway
Multiple myeloma (MM) is a malignant plasma cell disease. The activity of PIK3CG (PI3K catalytic subunit γ) is regulated directly by G-protein-coupled receptor and has been confirmed to be highly expressed in MM cells. This study aimed to determine the effect of pharmacological inhibition of PIK3CG...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023103732 |
| _version_ | 1797337073054646272 |
|---|---|
| author | Xiaotang Di Yiwen Pan Jinhua Yan Jing Liu Doudou Wen Hao Jiang Shubing Zhang |
| author_facet | Xiaotang Di Yiwen Pan Jinhua Yan Jing Liu Doudou Wen Hao Jiang Shubing Zhang |
| author_sort | Xiaotang Di |
| collection | DOAJ |
| description | Multiple myeloma (MM) is a malignant plasma cell disease. The activity of PIK3CG (PI3K catalytic subunit γ) is regulated directly by G-protein-coupled receptor and has been confirmed to be highly expressed in MM cells. This study aimed to determine the effect of pharmacological inhibition of PIK3CG on MM. We found that different concentrations of the PIK3CG inhibitor AS-605240 could suppress the growth of MM cell lines and the expression of c-Myc. The combination of PIK3CG inhibitor and the chemotherapy Melphalan could effectively inhibit the proliferation and migration of MM cells, promote the cell apoptosis, and decrease the ratio of Bcl-2/Bax and the expression of vimentin. The expression of proto-oncogene c-Myc was decreased and the sensitivity of cells to chemotherapeutic drugs was enhanced. Collectively, PIK3CG regulates growth of MM via c-Myc pathway, thus emerging as a promising molecular targeted therapy. |
| first_indexed | 2024-03-08T09:04:08Z |
| format | Article |
| id | doaj.art-1445513486fd4851b2c5aa72cc33a940 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T09:04:08Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-1445513486fd4851b2c5aa72cc33a9402024-02-01T06:30:54ZengElsevierHeliyon2405-84402024-01-01101e23165Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathwayXiaotang Di0Yiwen Pan1Jinhua Yan2Jing Liu3Doudou Wen4Hao Jiang5Shubing Zhang6Department of Cell Biology, School of Life Sciences, Central South University, Changsha, Hunan, 410013, ChinaDepartment of Cell Biology, School of Life Sciences, Central South University, Changsha, Hunan, 410013, China; The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710061, ChinaDepartment of Cell Biology, School of Life Sciences, Central South University, Changsha, Hunan, 410013, ChinaMolecular Biology Research Center, School of Life Sciences, Central South University, Changsha, Hunan, 410013, ChinaDepartment of Cell Biology, School of Life Sciences, Central South University, Changsha, Hunan, 410013, ChinaDepartment of Biomedical Informatics, School of Life Sciences, Central South University, Changsha, Hunan, 410013, China; Corresponding author. Department of Biomedical Informatics, School of Life Sciences, Central South University, 172# Tongzipo Road, Changsha, Hunan, 410013, China.Department of Cell Biology, School of Life Sciences, Central South University, Changsha, Hunan, 410013, China; Hunan Key Laboratory of Animal Models for Human Diseases, Central South University, Changsha, Hunan, 410013, China; Corresponding author. Department of Cell Biology, School of Life Sciences, Central South University, 172# Tongzipo Road, Changsha, Hunan, 410013, China.Multiple myeloma (MM) is a malignant plasma cell disease. The activity of PIK3CG (PI3K catalytic subunit γ) is regulated directly by G-protein-coupled receptor and has been confirmed to be highly expressed in MM cells. This study aimed to determine the effect of pharmacological inhibition of PIK3CG on MM. We found that different concentrations of the PIK3CG inhibitor AS-605240 could suppress the growth of MM cell lines and the expression of c-Myc. The combination of PIK3CG inhibitor and the chemotherapy Melphalan could effectively inhibit the proliferation and migration of MM cells, promote the cell apoptosis, and decrease the ratio of Bcl-2/Bax and the expression of vimentin. The expression of proto-oncogene c-Myc was decreased and the sensitivity of cells to chemotherapeutic drugs was enhanced. Collectively, PIK3CG regulates growth of MM via c-Myc pathway, thus emerging as a promising molecular targeted therapy.http://www.sciencedirect.com/science/article/pii/S2405844023103732Multiple myelomaPIK3CGc-MycMelphalanTargeted therapy |
| spellingShingle | Xiaotang Di Yiwen Pan Jinhua Yan Jing Liu Doudou Wen Hao Jiang Shubing Zhang Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway Heliyon Multiple myeloma PIK3CG c-Myc Melphalan Targeted therapy |
| title | Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway |
| title_full | Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway |
| title_fullStr | Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway |
| title_full_unstemmed | Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway |
| title_short | Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway |
| title_sort | therapeutic potential of anti pik3cg treatment for multiple myeloma via inhibiting c myc pathway |
| topic | Multiple myeloma PIK3CG c-Myc Melphalan Targeted therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023103732 |
| work_keys_str_mv | AT xiaotangdi therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway AT yiwenpan therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway AT jinhuayan therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway AT jingliu therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway AT doudouwen therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway AT haojiang therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway AT shubingzhang therapeuticpotentialofantipik3cgtreatmentformultiplemyelomaviainhibitingcmycpathway |